Patrick J Heron has an estimated net worth of $1.57 Billion. This is based on reported shares across multiple companies, which include GLAUKOS Corp, ANAPTYSBIO INC, Sierra Oncology, Inc., Tarsus Pharmaceuticals, Inc., Phathom Pharmaceuticals, Inc., Frazier Lifesciences Acquisition Corp, Arcutis Biotherapeutics, Inc., HilleVax, Inc., ALPINE IMMUNE SCIENCES, INC., Entasis Therapeutics Holdings Inc., MBX Biosciences, Inc., Vaxcyte, Inc., Trubion Pharmaceuticals, Inc, COLLEGIUM PHARMACEUTICAL, INC, Imago BioSciences, Inc., Mirum Pharmaceuticals, Inc., Cidara Therapeutics, Inc., Iterum Therapeutics plc, Passage BIO, Inc., Aptinyx Inc., and Regado Biosciences Inc.

2025 was Patrick J Heron's most active year for acquiring shares with 27 total transactions. Patrick J Heron's most active month to acquire stocks was the month of May. 2018 was Patrick J Heron's most active year for disposing of shares, totalling 14 transactions. Patrick J Heron's most active month to dispose stocks was the month of September. 2022 saw Patrick J Heron paying a total of $73,012,773.50 for 4,921,713 shares, this is the most they've acquired in one year. In 2025 Patrick J Heron cashed out on 8,558,239 shares for a total of $16,677,445.20, their largest year based on trade value.